<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295750</url>
  </required_header>
  <id_info>
    <org_study_id>FE200486 CS21</org_study_id>
    <nct_id>NCT00295750</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer</brief_title>
  <official_title>An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients With Prostate Cancer Requiring Androgen Ablation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was a three-arm, active-control, multi-centre, parallel group study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Testosterone &lt;=0.5ng/mL From Day 28 Through Day 364</measure>
    <time_frame>12 months</time_frame>
    <description>Kaplan-Maier estimates of the cumulative probabilities of testosterone &lt;=0.5 ng/mL from Day 28 to Day 364. The degarelix response rate estimation determined whether the lower bound of the 95% confidence interval for the cumulative probability of testosterone &lt;=0.5 ng/mL from Day 28 to Day 364 was no lower than 90%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Testosterone Surge During the First Two Weeks of Treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>A patient was defined as having a testosterone surge if the testosterone level exceeded baseline by &gt;=15% on any two days during the first two weeks of treatment (i.e. two of Study Days 1, 3, 7 and 14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Testosterone Level &lt;=0.5 ng/mL at Day 3</measure>
    <time_frame>3 days</time_frame>
    <description>This outcome measure presents the testosterone levels 3 days after the initial dose of trial medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Size of Testosterone Changes at Day 255 and/or Day 259 Compared to the Testosterone Level at Day 252</measure>
    <time_frame>Day 252, Day 255, and Day 259</time_frame>
    <description>Testosterone increases on Day 255 and/or on Day 259 (highest value of Day 255 and Day 259 was used) were compared with Day 252 values. Patients were categorised with shifts of &lt;=-0.25, &gt;-0.25-0, &gt;0-0.25, &gt;0.25-0.5 and &gt;0.5 ng/mL from mean testosterone levels on Day 252.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Prostate-specific Antigen From Baseline to Day 14 and Day 28</measure>
    <time_frame>Days 14 and 28</time_frame>
    <description>Percentage change from Baseline to Day 14 and Day 28 in prostate-specific antigen, which is a clinically important biological marker for treatment effect and prostate cancer progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Grouped by Time to Prostate-specific Antigen Failure</measure>
    <time_frame>12 months</time_frame>
    <description>The time to prostate specific antigen failure was defined as the days from first dosing (scheduled dosing days) where an increase in serum prostate specific antigen of ≥50% from nadir and a least 5 ng/mL measured on two consecutive occasions at least two weeks apart was noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Markedly Abnormal Change in Laboratory Variables (&gt;=20 Percent of Patients)</measure>
    <time_frame>Baseline to Day 364</time_frame>
    <description>Criteria for lab values changes from baseline to the end of the study considered markedly abnormal were set for each lab test. If 20% of patients reached that value, the results were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Value of QTc Interval as Measured by Electrocardiogram</measure>
    <time_frame>12 months</time_frame>
    <description>The QTc interval results are calculated with Fridericia's correction. QTc intervals are a standard evaluation of an electrocardiogram and help measure the risk of developing ventricular arrhythmias.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Markedly Abnormal Change in Vital Signs and Body Weight</measure>
    <time_frame>12 months</time_frame>
    <description>Vital signs and body weight included incidence of markedly abnormal changes from baseline to the end of the study in blood pressure (systolic and diastolic), pulse, and body weight at the end of trial as compared to baseline. The table presents the number of patients in each group with normal baseline and markedly abnormal value post-baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">620</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>degarelix 240/160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>degarelix 240/80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leuprolide 7.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Leuprolide (Lupron Depot) 7.5 mg IM (in the muscle) every 28 days starting at day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.</description>
    <arm_group_label>degarelix 240/160 mg</arm_group_label>
    <other_name>FE200486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.</description>
    <arm_group_label>degarelix 240/80 mg</arm_group_label>
    <other_name>FE 200486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide 7.5 mg</intervention_name>
    <description>Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.</description>
    <arm_group_label>Leuprolide 7.5 mg</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Patients, aged 18 years or over, with histologically proven prostate cancer of all
             stages in whom endocrine treatment is indicated.

          -  Baseline testosterone &gt;1.5 ng/mL.

          -  Life expectancy of at least 12 months.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology Centers of Alabama</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alaska Clinical Research Center, LLC</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Urology Medical Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Clinical Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simi-San Faernando Valley Urology Associates</name>
      <address>
        <city>Granada Hills</city>
        <state>California</state>
        <zip>91344</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Orange County Medical Research Center</name>
      <address>
        <city>Laguna Woods,</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Clinical Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associate PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Foundation for Healthcare Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrenceville Urology</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jay A. Motola, MD, FACS</name>
      <address>
        <city>Carmel</city>
        <state>New York</state>
        <zip>10512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Urology Research</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State College Urologic Association</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy Urological Research Institute</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Urological Research Institute</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Strand Urology</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Jeffrey Frankel</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruce W. Palmer Urology Inc, 125-70 Exhibition Street</name>
      <address>
        <city>Kentville</city>
        <state>Nova Scotia</state>
        <zip>B4N 4KB</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jindrichuv Hradec a.s., U Nemocnice 380/III</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>37738</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Klinik, Universitatsklinikum Mannheim, Theodor-Kutzer-Ufer 1-3</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szeged M.J.V.O. Korhaza, Urologiai Osztaly, Kalvaria sugarut 57</name>
      <address>
        <city>Szeged</city>
        <zip>H-6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General &quot;Dr Santiago Ramon y Cajal&quot;, ISSSTE</name>
      <address>
        <city>Predio Canoas S/N</city>
        <state>Durango, DGO</state>
        <zip>34079</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium MC, Henri Dunantstraat 5</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cristo Redentor Hospital</name>
      <address>
        <city>La Hacienda</city>
        <zip>00784</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan VA Medical Center</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Provita Center, 2 Primaverii Street</name>
      <address>
        <city>Constanta</city>
        <zip>900635</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andros Urology Clinic, Ulitsa Lenina 36A</name>
      <address>
        <city>St Petersburg</city>
        <zip>197136</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiev City Clinical Hospital #3, Petr Ivaschenko 26, Petra Zaporogtsa str.</name>
      <address>
        <city>Kiev</city>
        <zip>2125</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital, Derriford Road</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x.</citation>
    <PMID>19035858</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2006</study_first_submitted>
  <study_first_submitted_qc>February 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <results_first_submitted>January 5, 2009</results_first_submitted>
  <results_first_submitted_qc>March 13, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2009</results_first_posted>
  <last_update_submitted>December 17, 2012</last_update_submitted>
  <last_update_submitted_qc>December 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Degarelix 240/160 mg</title>
          <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.</description>
        </group>
        <group group_id="P2">
          <title>Degarelix 240/80 mg</title>
          <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.</description>
        </group>
        <group group_id="P3">
          <title>Leuprolide 7.5 mg</title>
          <description>Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="206">randomized</participants>
                <participants group_id="P2" count="210">randomized</participants>
                <participants group_id="P3" count="204">randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-treat (ITT) Population</title>
              <participants_list>
                <participants group_id="P1" count="202">randomized and exposed patients</participants>
                <participants group_id="P2" count="207">randomized and exposed patients</participants>
                <participants group_id="P3" count="201">randomized and exposed patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Taking prohibited therapy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative errors</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial drug errors</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but never received trial drug</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Degarelix 240/160 mg</title>
          <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.</description>
        </group>
        <group group_id="B2">
          <title>Degarelix 240/80 mg</title>
          <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Leuprolide 7.5 mg</title>
          <description>Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="202"/>
            <count group_id="B2" value="207"/>
            <count group_id="B3" value="201"/>
            <count group_id="B4" value="610"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Intent-to-treat (ITT) population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="163"/>
                    <measurement group_id="B4" value="492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>ITT population.</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="8.47" lower_limit="50" upper_limit="88"/>
                    <measurement group_id="B2" value="72" spread="8.12" lower_limit="51" upper_limit="89"/>
                    <measurement group_id="B3" value="74" spread="8.77" lower_limit="52" upper_limit="98"/>
                    <measurement group_id="B4" value="73" spread="8.45" lower_limit="50" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>ITT population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="201"/>
                    <measurement group_id="B4" value="610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>ITT population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="172"/>
                    <measurement group_id="B4" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>ITT population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Curative Intent</title>
          <description>ITT population. Curative intent refers to radical prostatectomy or radiotherapy.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="177"/>
                    <measurement group_id="B4" value="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason Score</title>
          <description>ITT population. The Gleason score is a system of grading the aggressiveness of the prostate cancer and how fast it is likely to grow and spread. Scale is 2-10, with low numbers being the least aggressive and 10 being the most aggressive. Gleason scores were unavailable for 3 patients.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of Prostate Cancer</title>
          <description>ITT population. Stage of prostate cancer was classified according to the Tumour, Nodule and Metastatic classification that is a cancer staging system that describes the extent of cancer. T describes the size of the tumor and whether it has invaded nearby tissue, N describes regional lymph nodes that are involved, and M describes distant metastasis</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Localized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally advanced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not classifiable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>ITT population</description>
          <units>kilogram per square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="3.70"/>
                    <measurement group_id="B2" value="26.7" spread="4.21"/>
                    <measurement group_id="B3" value="26.9" spread="3.86"/>
                    <measurement group_id="B4" value="26.8" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Prostate-specific Antigen Levels</title>
          <units>nanogram per milliliter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.9" lower_limit="8.2" upper_limit="68"/>
                    <measurement group_id="B2" value="19.8" lower_limit="9.4" upper_limit="46"/>
                    <measurement group_id="B3" value="19.0" lower_limit="8.7" upper_limit="57"/>
                    <measurement group_id="B4" value="19.0" lower_limit="8.7" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Testosterone Levels</title>
          <units>nanogram per milliliter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.78" lower_limit="2.86" upper_limit="5.05"/>
                    <measurement group_id="B2" value="4.11" lower_limit="3.05" upper_limit="5.32"/>
                    <measurement group_id="B3" value="3.84" lower_limit="2.91" upper_limit="5.01"/>
                    <measurement group_id="B4" value="3.93" lower_limit="2.89" upper_limit="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since Prostate Cancer Diagnosis</title>
          <description>ITT population.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="485" spread="1109"/>
                    <measurement group_id="B2" value="491" spread="994"/>
                    <measurement group_id="B3" value="497" spread="1088"/>
                    <measurement group_id="B4" value="491" spread="1063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>ITT population</description>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.7" spread="13.0"/>
                    <measurement group_id="B2" value="79.8" spread="14.9"/>
                    <measurement group_id="B3" value="79.4" spread="12.2"/>
                    <measurement group_id="B4" value="79.3" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Testosterone &lt;=0.5ng/mL From Day 28 Through Day 364</title>
        <description>Kaplan-Maier estimates of the cumulative probabilities of testosterone &lt;=0.5 ng/mL from Day 28 to Day 364. The degarelix response rate estimation determined whether the lower bound of the 95% confidence interval for the cumulative probability of testosterone &lt;=0.5 ng/mL from Day 28 to Day 364 was no lower than 90%.</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 240/160 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 240/80 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Leuprolide 7.5 mg</title>
            <description>Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Testosterone &lt;=0.5ng/mL From Day 28 Through Day 364</title>
          <description>Kaplan-Maier estimates of the cumulative probabilities of testosterone &lt;=0.5 ng/mL from Day 28 to Day 364. The degarelix response rate estimation determined whether the lower bound of the 95% confidence interval for the cumulative probability of testosterone &lt;=0.5 ng/mL from Day 28 to Day 364 was no lower than 90%.</description>
          <population>Intent-to-treat (ITT) population.</population>
          <units>percentage of patients</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="94.8" upper_limit="99.4"/>
                    <measurement group_id="O2" value="97.2" lower_limit="93.5" upper_limit="98.8"/>
                    <measurement group_id="O3" value="96.4" lower_limit="92.5" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A non-inferiority assessment determined whether degarelix was non-inferior to leuprolide with respect to the cumulative probability of testosterone &lt;=0.5 ng/mL from Day 28 to Day 364.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority limit was -10 percentage points.</non_inferiority_desc>
            <param_type>Difference in cumulative probability</param_type>
            <param_value>1.9</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A non-inferiority assessment determined whether degarelix was non-inferior to leuprolide with respect to the cumulative probability of testosterone &lt;=0.5 ng/mL from Day 28 to Day 364.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority limit was -10 percentage points.</non_inferiority_desc>
            <param_type>Difference in cumulative probability</param_type>
            <param_value>0.9</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Testosterone Surge During the First Two Weeks of Treatment</title>
        <description>A patient was defined as having a testosterone surge if the testosterone level exceeded baseline by &gt;=15% on any two days during the first two weeks of treatment (i.e. two of Study Days 1, 3, 7 and 14).</description>
        <time_frame>2 weeks</time_frame>
        <population>ITT population. If one or more of the testosterone values on Days 1, 3, 7 or 14 was missing, the last observation was carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 240/160 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 240/80 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Leuprolide 7.5 mg</title>
            <description>Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Testosterone Surge During the First Two Weeks of Treatment</title>
          <description>A patient was defined as having a testosterone surge if the testosterone level exceeded baseline by &gt;=15% on any two days during the first two weeks of treatment (i.e. two of Study Days 1, 3, 7 and 14).</description>
          <population>ITT population. If one or more of the testosterone values on Days 1, 3, 7 or 14 was missing, the last observation was carried forward.</population>
          <units>percentage of patients</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.0" upper_limit="2.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="1.8"/>
                    <measurement group_id="O3" value="80.1" lower_limit="73.9" upper_limit="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Testosterone Level &lt;=0.5 ng/mL at Day 3</title>
        <description>This outcome measure presents the testosterone levels 3 days after the initial dose of trial medication.</description>
        <time_frame>3 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 240/160 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 240/80 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Leuprolide 7.5 mg</title>
            <description>Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Testosterone Level &lt;=0.5 ng/mL at Day 3</title>
          <description>This outcome measure presents the testosterone levels 3 days after the initial dose of trial medication.</description>
          <population>ITT population.</population>
          <units>percentage of patients</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="91.7" upper_limit="97.9"/>
                    <measurement group_id="O2" value="96.1" lower_limit="92.5" upper_limit="98.3"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Size of Testosterone Changes at Day 255 and/or Day 259 Compared to the Testosterone Level at Day 252</title>
        <description>Testosterone increases on Day 255 and/or on Day 259 (highest value of Day 255 and Day 259 was used) were compared with Day 252 values. Patients were categorised with shifts of &lt;=-0.25, &gt;-0.25-0, &gt;0-0.25, &gt;0.25-0.5 and &gt;0.5 ng/mL from mean testosterone levels on Day 252.</description>
        <time_frame>Day 252, Day 255, and Day 259</time_frame>
        <population>ITT population who had blood samples drawn on Day 252, Day 255, and Day 259.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 240/160 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 240/80 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Leuprolide 7.5 mg</title>
            <description>Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Size of Testosterone Changes at Day 255 and/or Day 259 Compared to the Testosterone Level at Day 252</title>
          <description>Testosterone increases on Day 255 and/or on Day 259 (highest value of Day 255 and Day 259 was used) were compared with Day 252 values. Patients were categorised with shifts of &lt;=-0.25, &gt;-0.25-0, &gt;0-0.25, &gt;0.25-0.5 and &gt;0.5 ng/mL from mean testosterone levels on Day 252.</description>
          <population>ITT population who had blood samples drawn on Day 252, Day 255, and Day 259.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=-0.25 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;-0.25-0 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;0-0.25 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;0.25-0.5 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;0.5 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Prostate-specific Antigen From Baseline to Day 14 and Day 28</title>
        <description>Percentage change from Baseline to Day 14 and Day 28 in prostate-specific antigen, which is a clinically important biological marker for treatment effect and prostate cancer progression.</description>
        <time_frame>Days 14 and 28</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 240/160 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 240/80 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Leuprolide 7.5 mg</title>
            <description>Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Prostate-specific Antigen From Baseline to Day 14 and Day 28</title>
          <description>Percentage change from Baseline to Day 14 and Day 28 in prostate-specific antigen, which is a clinically important biological marker for treatment effect and prostate cancer progression.</description>
          <population>ITT population.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.6" lower_limit="-77.8" upper_limit="-40.8"/>
                    <measurement group_id="O2" value="-63.4" lower_limit="-77.1" upper_limit="-48.4"/>
                    <measurement group_id="O3" value="-17.9" lower_limit="-35.5" upper_limit="-5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-82.3" lower_limit="-91.4" upper_limit="-68.3"/>
                    <measurement group_id="O2" value="-84.9" lower_limit="-91.6" upper_limit="-73.2"/>
                    <measurement group_id="O3" value="-66.7" lower_limit="-81.3" upper_limit="-47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percentage change from baseline to Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percentage change from baseline to Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percentage change from baseline to Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percentage change from baseline to Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Grouped by Time to Prostate-specific Antigen Failure</title>
        <description>The time to prostate specific antigen failure was defined as the days from first dosing (scheduled dosing days) where an increase in serum prostate specific antigen of ≥50% from nadir and a least 5 ng/mL measured on two consecutive occasions at least two weeks apart was noted.</description>
        <time_frame>12 months</time_frame>
        <population>ITT population. Missing values were not imputed for this endpoint. Number in table represents the number of patients with prostate-specific antigen failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 240/160 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 240/80 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Leuprolide 7.5 mg</title>
            <description>Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Grouped by Time to Prostate-specific Antigen Failure</title>
          <description>The time to prostate specific antigen failure was defined as the days from first dosing (scheduled dosing days) where an increase in serum prostate specific antigen of ≥50% from nadir and a least 5 ng/mL measured on two consecutive occasions at least two weeks apart was noted.</description>
          <population>ITT population. Missing values were not imputed for this endpoint. Number in table represents the number of patients with prostate-specific antigen failure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0-28 (patients at risk=193, 201, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0-56 (patients at risk=192, 197, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0-84 (patients at risk=190, 193, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0-112 (patients at risk=190, 189, 188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0-140 (patients at risk=187, 187, 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0-168 (patients at risk=179, 185, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0-196 (patients at risk=173, 181, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0-224 (patients at risk=168, 175, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0-252 (patients at risk=165, 169, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0-280 (patients at risk=157, 165, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0-308 (patients at risk=153, 161, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0-336 (patients at risk=149, 156, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0-364 (patients at risk=149, 155, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cumulative probability</param_type>
            <param_value>85.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>79.8</ci_lower_limit>
            <ci_upper_limit>90.1</ci_upper_limit>
            <estimate_desc>95% confidence interval for the cumulative probability of completing the study without prostate specific antigen failure from Day 0 to Day 364.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cumulative probability</param_type>
            <param_value>91.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>85.9</ci_lower_limit>
            <ci_upper_limit>94.5</ci_upper_limit>
            <estimate_desc>95% confidence interval for the cumulative probability of completing the study without prostate specific antigen failure from Day 0 to Day 364.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cumulative probability</param_type>
            <param_value>85.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>79.9</ci_lower_limit>
            <ci_upper_limit>90.2</ci_upper_limit>
            <estimate_desc>95% confidence interval for the cumulative probability of completing the study without prostate specific antigen failure from Day 0 to Day 364.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Markedly Abnormal Change in Laboratory Variables (&gt;=20 Percent of Patients)</title>
        <description>Criteria for lab values changes from baseline to the end of the study considered markedly abnormal were set for each lab test. If 20% of patients reached that value, the results were reported.</description>
        <time_frame>Baseline to Day 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 240/160 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 240/80 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Leuprolide 7.5 mg</title>
            <description>Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Markedly Abnormal Change in Laboratory Variables (&gt;=20 Percent of Patients)</title>
          <description>Criteria for lab values changes from baseline to the end of the study considered markedly abnormal were set for each lab test. If 20% of patients reached that value, the results were reported.</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Haematocrit (&lt;=0.37 ratio)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoglobin (&lt;=115 g/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Urea Nitrogen (&gt;=10.7 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Protein (&gt;=2 units from baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Bacteria (0 at baseline and &gt;0 on treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Value of QTc Interval as Measured by Electrocardiogram</title>
        <description>The QTc interval results are calculated with Fridericia’s correction. QTc intervals are a standard evaluation of an electrocardiogram and help measure the risk of developing ventricular arrhythmias.</description>
        <time_frame>12 months</time_frame>
        <population>ITT population. End of Study values obtained at day 364 (+-7 days) for patients who completed. Patients who withdrew early had variable timeframes for the end of study value.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 240/160 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 240/80 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Leuprolide 7.5 mg</title>
            <description>Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Value of QTc Interval as Measured by Electrocardiogram</title>
          <description>The QTc interval results are calculated with Fridericia’s correction. QTc intervals are a standard evaluation of an electrocardiogram and help measure the risk of developing ventricular arrhythmias.</description>
          <population>ITT population. End of Study values obtained at day 364 (+-7 days) for patients who completed. Patients who withdrew early had variable timeframes for the end of study value.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Day 0 (n=202, 207, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403" spread="20.2"/>
                    <measurement group_id="O2" value="407" spread="21.6"/>
                    <measurement group_id="O3" value="404" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=195, 204, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404" spread="22.1"/>
                    <measurement group_id="O2" value="411" spread="23.5"/>
                    <measurement group_id="O3" value="405" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of study 12 months (n=202, 207, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415" spread="21.7"/>
                    <measurement group_id="O2" value="420" spread="22.3"/>
                    <measurement group_id="O3" value="419" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Markedly Abnormal Change in Vital Signs and Body Weight</title>
        <description>Vital signs and body weight included incidence of markedly abnormal changes from baseline to the end of the study in blood pressure (systolic and diastolic), pulse, and body weight at the end of trial as compared to baseline. The table presents the number of patients in each group with normal baseline and markedly abnormal value post-baseline.</description>
        <time_frame>12 months</time_frame>
        <population>ITT population. The first value in the category represents the actual clinical reading and the second is the change from baseline for blood pressure (units: millimeters of mercury) and heart rate (units:beats per minute). The weight category includes patients whose percent weight change from baseline fit the stated ranges.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 240/160 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 240/80 mg</title>
            <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Leuprolide 7.5 mg</title>
            <description>Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Markedly Abnormal Change in Vital Signs and Body Weight</title>
          <description>Vital signs and body weight included incidence of markedly abnormal changes from baseline to the end of the study in blood pressure (systolic and diastolic), pulse, and body weight at the end of trial as compared to baseline. The table presents the number of patients in each group with normal baseline and markedly abnormal value post-baseline.</description>
          <population>ITT population. The first value in the category represents the actual clinical reading and the second is the change from baseline for blood pressure (units: millimeters of mercury) and heart rate (units:beats per minute). The weight category includes patients whose percent weight change from baseline fit the stated ranges.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure &lt;=90 and decrease &gt;=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure &gt;=180 and increase &gt;=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure &lt;=50 and decrease &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure &gt;=105 and increase &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate &lt;=50 and decrease &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate &gt;=120 and increase &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body weight decrease of &gt;=7 percent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body weight increase of &gt;=7 percent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Degarelix 240/160 mg</title>
          <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.</description>
        </group>
        <group group_id="E2">
          <title>Degarelix 240/80 mg</title>
          <description>Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.</description>
        </group>
        <group group_id="E3">
          <title>Leuprolide 7.5 mg</title>
          <description>Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24"/>
                <counts group_id="E2" subjects_affected="21"/>
                <counts group_id="E3" subjects_affected="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Myopericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prostate examination abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Electrocardiogram (ECG) signs of myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Malignant lymphoma unclassifiable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Linitis plastica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pleural mesothelioma malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hyperkinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="165"/>
                <counts group_id="E2" subjects_affected="162"/>
                <counts group_id="E3" subjects_affected="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="207"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="108" subjects_affected="61" subjects_at_risk="202"/>
                <counts group_id="E2" events="114" subjects_affected="58" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="63" subjects_affected="48" subjects_at_risk="202"/>
                <counts group_id="E2" events="56" subjects_affected="36" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="23" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" events="24" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E2" events="19" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="207"/>
                <counts group_id="E3" events="25" subjects_affected="18" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="202"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="207"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="202"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="207"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Aspartate aminostransferase increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="207"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E3" events="20" subjects_affected="18" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="59" subjects_affected="53" subjects_at_risk="202"/>
                <counts group_id="E2" events="71" subjects_affected="53" subjects_at_risk="207"/>
                <counts group_id="E3" events="50" subjects_affected="43" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ferring Pharmaceuticals</name_or_title>
      <organization>Clinical Development Support</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

